OncoREX p53 Cancer Array
Cancer drug screening and discovery. The OncoRex p53 Cancer Array provides a biologically relevant screening tool since all p53 variants are correctly folded and functional using the patented KREX ® protein folding technology. Using the array, Sengenics can screen your therapeutic antibodies and protein binding compounds against more than 100 p53 wildtype and mutant variants by measuring their impact on DNA binding as a func…
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
The OncoRex p53 Cancer Array provides a biologically relevant screening tool since all p53 variants are correctly folded and functional using the patented KREX® protein folding technology. Using the array, Sengenics can screen your therapeutic antibodies and protein binding compounds against more than 100 p53 wildtype and mutant variants by measuring their impact on DNA binding as a functional readout.
Autoantibodies: Powerful biomarkers in cancer precision medicine
Cancer is an abnormal, uncontrolled growth of cells that migrate from one tissue throughout the body, invading other distal tissues. Despite a long, thorough history of research, a cure has eluded scientists, primarily because of the heterogeneity of the disease. In this application note from Sengenics, explore the barriers to curing cancer, the relationship between cancer and autoantibodies, and the role of autoantibodies in personalised medicine.
Autoantibodies: The key to early diagnosis and improved patient stratification
Sengenics CSO and inventor of the KREX™ protein folding technology, Professor Jonathan Blackburn, discusses the applications of KREX™ for the discovery of autoantibody-based companion diagnostics and early disease detection biomarkers, as well as the potential benefits in the treatment of autoimmune disease, cancer, neurological and infectious diseases and beyond
